Top

Published in:

01-10-2016 | Case report

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs

Authors: Shunsuke Sugiyama, Mariko Ishizuka, Masanobu Takahashi, Keigo Komine, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Hideki Shimodaira, Chikashi Ishioka

Published in: International Cancer Conference Journal | Issue 4/2016

Abstract

A 60-year-old woman was admitted to a medical clinic because of epigastric pain. Esophagogastroduodenoscopy revealed a submucosal tumor in the upper gastric corpus and, the tumor was subsequently resected using partial gastrectomy. The pathological findings revealed that the tumor was a gastrointestinal stromal tumor. After 4 months of observation without any adjuvant treatment, the patient was found to have liver metastasis and she was admitted to our hospital for treatment. We successfully treated the patient through sequential drug therapies, including imatinib, nilotinib, sunitinib, and regorafenib, and maintaining disease control for more than 5 years.

Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer Netw 8(Suppl 2):S1–S41 (quiz S42–44)

Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480CrossRefPubMed

Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRefPubMed

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed

Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302CrossRefPubMed

Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419CrossRefPubMed

Rutkowski P, Bylina E, Wozniak A et al (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896CrossRefPubMed

Blay JY, Shen L, Kang YK et al (2015) Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 16:550–560CrossRefPubMedPubMedCentral

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

10.

Sawaki A, Nishida T, Doi T et al (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117:4633–4641CrossRefPubMed

11.

Kang YK, Ryu MH, Yoo C et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14:1175–1182CrossRefPubMedPubMedCentral

12.

Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774CrossRefPubMed

13.

Komatsu Y, Doi T, Sawaki A et al (2015) Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 20:905–912CrossRefPubMedPubMedCentral

Title: Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs
Authors: Shunsuke Sugiyama
Mariko Ishizuka
Masanobu Takahashi
Keigo Komine
Hiroo Imai
Ken Saijo
Masahiro Takahashi
Hidekazu Shirota
Shin Takahashi
Hideki Shimodaira
Chikashi Ishioka
Publication date: 01-10-2016
Publisher: Springer Japan
Published in: International Cancer Conference Journal / Issue 4/2016
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-016-0250-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

A rare case of hepatocellular carcinoma metastasizing hematogenously to the rectum

A case of hemorrhagic cystitis caused by nab-paclitaxel

Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report

Diffuse large B-cell lymphoma, not otherwise specified presenting with bone and bone marrow involvement in the absence of lymphadenopathy

Late recurrence of gastric cancer in the ovary and uterine cervix

Keynote webinar | Spotlight on antibody–drug conjugates in cancer